Clinical Oversight Review Board (CORB) Criteria for Prescribing

Loncastuximab tesirine-lpyl (Zynlonta)

Formulary **loncastuximab tesirine-lpyl (Zynlonta)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria and criteria for current OR new Kaiser Permanente members already taking the medication who have not been reviewed previously: Formulary loncastuximab tesirine-lpyl (Zynlonta) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Hematology/ Oncology provider
- Patient is at least 18 years of age
- Diagnosis of relapsed or refractory CD19+ diffuse large B-cell lymphoma
- Patient has a documented lack of response to at least 2 prior lines of systemic therapy

kp.org

Revised: 10/14/21 Effective: 12/16/21 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

